Last CNY9.95 CNY
Change Today +0.42 / 4.41%
Volume 21.0M
600351 On Other Exchanges
Symbol
Exchange
Shanghai
As of 3:05 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

yabao pharmaceutical group-a (600351) Snapshot

Open
CNY9.61
Previous Close
CNY9.53
Day High
CNY9.96
Day Low
CNY9.57
52 Week High
07/7/14 - CNY10.19
52 Week Low
12/23/13 - CNY5.77
Market Cap
6.9B
Average Volume 10 Days
9.0M
EPS TTM
CNY0.22
Shares Outstanding
692.0M
EX-Date
07/14/14
P/E TM
46.0x
Dividend
CNY0.06
Dividend Yield
0.60%
Current Stock Chart for YABAO PHARMACEUTICAL GROUP-A (600351)

Related News

No related news articles were found.

yabao pharmaceutical group-a (600351) Related Businessweek News

No Related Businessweek News Found

yabao pharmaceutical group-a (600351) Details

Yabao Pharmaceutical Group Co., Ltd, a specialty pharmaceutical company, is engaged in the research and development, manufacture, and operation of western and Chinese medicines, APIs, health care products, and packing materials for medicines in China and internationally. The company’s marketed products are in cardiovascular, oncology, pediatric, and women’s health areas; and research and development programs in diabetes, inflammation, and cerebrovascular areas. It also provides finished drug products in various forms, such as tablets, injections, capsules, granules, and suppositories, as well as in powders for injections; and TCM products. In addition, the company is involved in planting and processing medicinal herbs; and producing packing material for medicine, such as plastic bottles, adhesive labels, bottles cushions, carton boxes, cartons etc. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Yuncheng, China.

Founded in 1978

yabao pharmaceutical group-a (600351) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

yabao pharmaceutical group-a (600351) Key Developments

Yabao Pharmaceutical Group Co., Ltd to Report First Half, 2014 Results on Aug 20, 2014

Yabao Pharmaceutical Group Co., Ltd announced that they will report first half, 2014 results on Aug 20, 2014

Yabao Pharmaceutical Co, Inc and Changzhou Le Sun Pharmaceuticals Ltd Enter an Partnership to Develop Early-Stage Oncology Compound

Yabao Pharmaceutical Co Inc. announced a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd.to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development. This unique partnership represents a creative approach to accelerate the development of an oncology compound in China for the globe, by leveraging the complementary strengths of a premier Chinese pharmaceutical company and a world-class medicinal chemistry and drug discovery expertise. Under the terms of the agreement, Yabao receives exclusive rights to develop and commercialize LS-008 in China while Changzhou Le Sun Pharmaceuticals Ltd. retains majority of exclusive rights in all other markets. The parties will together determine the strategic development plan, which will be performed primarily by Yabao in China under global GLP, GMP and GCP standards.

Yabao Pharma and Eli Lilly to Jointly Develop Diabetes Treatment

Yabao Pharmaceutical has entered into a strategic partnership with Eli Lilly and Company to jointly develop Lilly's glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the US in addition to extensive pre-clinical development. GKAs have the potential to differentiate from other anti-diabetic agents by exerting two potentially beneficial actions: promoting insulin secretion and decreasing glucose production by the liver. As a result, GKAs may exert powerful anti-hyperglycemic effects, even in patients who are relatively unresponsive to other oral drugs. As part of the deal, Yabao will secure rights to develop and commercialize the GKA compound in China and Lilly retains rights in all other markets. Both the firms will collaborate to determine a strategic development plan for China, while Yabao will initially be responsible to perform and fund all development, with Lilly having future buy-in options for China.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600351:CH CNY9.95 CNY +0.42

600351 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600351.
View Industry Companies
 

Industry Analysis

600351

Industry Average

Valuation 600351 Industry Range
Price/Earnings 53.0x
Price/Sales 3.9x
Price/Book 3.9x
Price/Cash Flow 52.6x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YABAO PHARMACEUTICAL GROUP-A, please visit www.yabao.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.